<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40538">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02578641</url>
  </required_header>
  <id_info>
    <org_study_id>FF01</org_study_id>
    <nct_id>NCT02578641</nct_id>
  </id_info>
  <brief_title>Multicentre, Randomized, Open-Label, Phase III Clinical Trial for Advanced Nasopharyngeal Carcinoma Patients</brief_title>
  <official_title>A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tessa Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tessa Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, randomized, open label, Phase III clinical trial.

      Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to
      stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Giving an infusion of a person's cytotoxic T lymphocytes (CTL) that have been
      treated in the laboratory may help the body build an effective immune response to kill tumor
      cells. Giving combination chemotherapy together with laboratory-treated T lymphocytes may
      kill more tumor cells. This Phase III trial is to assess if combined gemcitabine-carboplatin
      (GC) followed by adoptive T-cell therapy would improve clinical outcome for patients with
      advanced nasopharyngeal carcinoma (NPC). It is also the world's first, and largest, Phase 3
      T-cell therapy cancer trial ever conducted, and enrollment is ongoing for 330 patients from
      29 hospital centers across Asia and the United States.

      This clinical trial is conducted on the back of a successful Phase 2 NPC trial involving 38
      patients at the National Cancer Centre, Singapore. This trial produced the best published
      2-year (62.9%), and median overall survival (OS) data (29.9 months) in 35 patients with
      advanced NPC who received autologous EBV-specific CTL. Kindly see
      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978790/ for the Phase 2 publication titled
      &quot;Adoptive T-cell Transfer and Chemotherapy in the First line treatment of Metastatic and/or
      Locally Recurrent Nasopharyngeal Carcinoma&quot;.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      330 patients will be randomized after their eligibility status has been fully determined and
      informed consent has been obtained. Patients will be randomly allocated to receive either
      Arm A (Gemcitabine and Carboplatin (GC) x 4 cycles and EBV-specific CTL) or Arm B (GC x 6
      cycles alone) in a 1:1 ratio using a stratified block randomization scheme. The
      stratification variables are country and disease stage (metastatic vs locally recurrent)

      After randomization, patients in Arm A will have their peripheral blood taken for the
      establishment of cytotoxic T cell line and EBV transformed lymphoblastoid cell line (CTL).
      Within two weeks of enrollment, patients will commence combination GC chemotherapy for a
      total of 4 cycles. Patients in Stage 2 of study will receive the EBV-specific CTL
      immunotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolonging Overall Survival</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Assess the efficacy of CTL following first line chemotherapy in prolonging Overall Survival (OS) of patients with advanced NPC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Assess the efficacy of CTL in delaying disease progression (PFS) in patients with advanced NPC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Tumor assessment will be according to RECIST 1.1 criteria. Compare the Overall Response Rate under the 2 treatment arms. This is based on the proportion of individuals who achieve a further response (Complete Response or Partial Response) after immunotherapy using preimmunotherapy imaging as baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Compare the Clinical Benefit Rate under the 2 treatment arms.Clinical Benefit rate (CBR) is defined as the proportion of patients who achieve Complete Response, Partial Response, Stable Disease to both chemotherapy and then, for Arm A, to immunotherapy using pre immunotherapy (post cycle 4 chemotherapy) imaging as a baseline. Tumor assessment will be according to RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life of patients</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Compare the Quality of Life of patients based on EORTC QLQ-C30 under the 2 treatment arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Nasopharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of combination IV Gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days, followed sequentially by T-cell immunotherapy (2 cycles) of autologous EBV specific Cytotoxic T Lymphocytes every 2 weeks, followed by EBV-specific CTL immunotherapy (4 cycles) every 8 weeks after 6 weeks from the second cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 cycles of combination IV gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous EBV specific Cytotoxic T Lymphocytes</intervention_name>
    <description>The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combination IV gemcitabine and IV carboplatin (AUC2)</intervention_name>
    <description>4 cycles for Arm A and 6 cycles for Arm B</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria

          1. Metastatic or locally recurrent EBV-positive, non-keratinizing and/ or
             undifferentiated NPC* who do not have curative options such as chemo-radiation or
             surgery

             *Subjects will be enrolled based on confirmed histology diagnosis of the NPC

          2. Radiologically measurable disease

          3. Human Immunodeficiency Virus (HIV) negative*

             * Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests
             available within 12 months before screening or at screening

          4. Bilirubin &lt;2 x upper limit of normal (ULN) and aspartate aminotransferase (AST),
             alanine aminotransferase (ALT) &lt;3 x ULN

          5. Calculated creatinine clearance (CRCL) ≥40 mL/min. Glomerular Filtration Rate (GFR)
             is calculated based on Cockcroft-Gault method.

          6. Normal corrected calcium levels

          7. Absolute neutrophil count &gt;1200/mm3, hemoglobin (Hb) ≥10 g/dL and platelets
             ≥100,000/mm3

          8. Male or female

          9. Age ≥21 years

         10. Eastern Cooperative Oncology Group Performance Scale (ECOG-PS) ≤2

         11. Written informed consent

         12. Life expectancy &gt;6 months

        Key Exclusion Criteria

          1. Severe concomitant illness i.e. chronic obstructive pulmonary disease (COPD),
             ischemic heart disease (IHD), active congestive cardiac failure (CCF), active angina
             pectoris, uncontrolled arrhythmia, uncontrolled hypertension

          2. HIV Positive*

             * Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests
             available within 12 months before screening or at screening

          3. Pregnant or lactating females

          4. Refuse of use of contraception during trial (both male and female patients)

          5. Investigational therapy less than one month prior to study entry

          6. Pre-existing peripheral neuropathy (National Cancer Institute Common Terminology
             Criteria for Adverse Events [NCI CTCAE] ≥2)

          7. Central nervous system metastasis

          8. Previous or concurrent cancer that is distinct in primary site or histology from the
             cancer being evaluated in this study, EXCEPT cervical carcinoma in situ, treated
             basal cell carcinoma, superficial bladder tumors [Ta, Tis and T1] or any cancer
             curatively treated &gt;3 years prior to study entry

          9. Positive hepatitis B surface antigen (HBsAg) results

         10. Known history of hepatitis C and recovery status has not been determined at time of
             screening

         11. Prior chemotherapy for metastatic or locally recurrent disease

        Exceptions:

          -  Prior radiotherapy with curative intent

          -  Prior chemo-radiotherapy with curative intent

          -  Adjuvant chemotherapy

          -  Localised palliative radiotherapy Prior chemotherapy must be &gt; 6 months before
             screening 12) Severe intercurrent infections 13) Prior immunotherapy for metastatic
             or locally recurrent disease

        Exception:

        • Adjuvant immunotherapy/ biologics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han Chong TOH</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Centre Singapore (NCCS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PAULINE HOON Director, Regulatory Affairs</last_name>
    <phone>65 6384 0755</phone>
    <email>clinicaltrials@tessatherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hwee Hwee TEY Head, Project Management</last_name>
    <phone>65 6222 2655</phone>
    <email>hweehwee-tey@cmicgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erminia Massarelli, M.D., Ph.D., M.S.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alain Algazi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>A. Dimitrios Colevas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/ Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lori J Wirth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eric Nadler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Premal Lulla, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sultan Ismail</name>
      <address>
        <city>Johor Bahru</city>
        <zip>81100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ai Lian Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beacon International Specialist Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>46050</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lye Mun Tho, M.B.B.S, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Harissa Husainy Hasbullah, MCO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>506603</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gwo Fuang Ho, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pantai Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Low, M.B.B.S</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penang Adventist Hospital</name>
      <address>
        <city>Penang</city>
        <zip>10350</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Soo Fan Ang, M.B.B.S</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Miriam Cancer Hospital</name>
      <address>
        <city>Penang</city>
        <zip>11200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kean Fatt Ho, MB BCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mei Kim Ang, MB BCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Akhil Chopra, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tai-Lin Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ching-Yun Hsieh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jin-Ching Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ruey-Long Hong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Muh-Hwa Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LinKou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hung-Ming Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chawalit Lertbutsayanukul, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ekaphop Sirachainan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maharat Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Imjai Chitapanrux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital, Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kosin Wirasorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lopburi Cancer Hospital</name>
      <address>
        <city>Lopburi</city>
        <zip>15000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jirasak Sukhaboon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ubonratchathani Cancer Hospital</name>
      <address>
        <city>Ubon Ratchathani</city>
        <zip>34000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thanut Khuayjarernpanishk, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Udonthani Cancer Hospital</name>
      <address>
        <city>Udon Thani</city>
        <zip>41000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tharathon Tungkasamit, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tessatherapeutics.com/</url>
    <description>Sponsor</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 2, 2017</lastchanged_date>
  <firstreceived_date>October 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>Epstein-Barr Virus</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>Cytotoxic T Lymphocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
